Masayuki Tsuchiya

President, CEO at Complecure, Inc.

Speaker

I am the President and CEO of Complecure Inc., a drug discovery startup company. I have over 30 years of experience working in the research and development division at Chugai Pharmaceutical in Japan. In particular, I was involved in establishing Chugai’s research infrastructure for biopharmaceuticals and antibody drugs. A notable achievement was the successful development of Japan’s first humanized antibody drug, a humanized anti-human IL-6 receptor antibody (product name:ACTEMRA) by a collaboration with Medical Research Council (MRC) in London. In 2015, I left Chugai Pharmaceutical and joined Epsilon Molecular Engineering (EME) Inc, a startup at Saitama University, as Director and CTO, where I successfully built a humanized VHH antibody library, and an agonistic VHH drug. Then in 2024, I became President and CEO of Complecure Inc., a startup at the University of Tokyo. At Complecure, we are working on the development of new ADC formulations, including technologies for constructing ADC formulations composed of non-covalent bonds as next-generation ADC technology. In this presentation, I will introduce our AMDC technology.